Attendee search 

Anavex™ Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer, which have significant unmet medical needs.

ANAVEX™ 2-73, the Company’s orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg.  Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.

A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®).  The combined therapeutics, referred to as “ANAVEX™ PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.

ANAVEX PLUS is believed to be a compelling commercial opportunity.  The clinical trial risk is lower because donepezil (Aricept®) is already on the market, with global sales of $4-billion annually.  Donepezil (Aricept®) is now generic and a patent application has been filed for ANAVEX PLUS which, if granted, would provide protection until 2033.

Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.

HEALTHePRACTICES (HeP) provides expertise in assisting healthcare practices and technology companies to achieve specific goals toward the delivery of excellent care to their clients. We provide Business Development and Consulting support with a focus on all aspects of telemedicine with a particular interest in medical imaging.

French BioBeach is a Life Science Catalyst between France & Southern California, Enabling and Fostering Business Relationships. We work with SoCal companies on their European Expansion and with French companies on their US expansion. We facilitate Partnering Opportunities and/or Physical Implantation (incubator).

Covalent Development facilite le développement de votre portefeuille clients et de votre chiffre d'affaires en Amérique du Nord. Nous sommes spécialisés dans la vente de services complexes et innovants à l'Industrie Pharmaceutique et Cosmétique.

Based in Central New Jersey, Covalent Development offers to develop US business activities of Biotech companies.  
The state of New Jersey is home to more than 300 biotechnology companies and 20 pharmaceutical and medical technology firms (17 out of the world’s top 20 have major facilities in the state). This incredible concentration offers extraordinary opportunities to develop your business.  
New York, Boston, Washington DC, North Carolina and Philadelphia are close and there is only 3 hours of time difference with West Coast. It makes things easier to reach your prospects and clients!

----

Basée dans le centre du New Jersey, Covalent Development propose de développer vos activités aux Etats-Unis. 
L'état du New Jersey héberge plus de 300 entreprises de biotechnologie ainsi que 20 sociétés pharmaceutiques et médicales (17 du top 20 sont implantées dans l'état). C'est une localisation idéale pour développer votre business. 
New York, Boston, Washington DC, la Caroline du Nord et Philadelphia sont proches et il n'y a que 3 heures de décalage horaire avec la côte ouest. De quoi faciliter les échanges avec vos prospects et clients ! 

DiamondRock, a lodging-focused MD corporation operates as a real estate investment trust (REIT), owns a portfolio of 29 premium hotels & resorts containing ~10,900 rooms, concentrated in key gateway cities and destination resorts throughout North America and the U.S.V.I. Our vision is to be the premier allocator of capital in the lodging industry and our goal is to deliver above-average shareholder returns across the full lodging cycle. We strive to differentiate ourselves from peers by executing on three strategic principles: 

- Maintaining a balanced portfolio of high-quality assets with superior growth prospects in markets that have high barriers to entry. 
- Employing disciplined and innovative approaches to asset management that drive meaningful upside to underlying performance. 
- Preserving a clean, conservative balance sheet that supports strategic and financial flexibility, dividends and shareholder returns. 

As an owner, as opposed to an operator, we receive all operating profits or losses generated by our hotels after we pay fees to the hotel managers, which are based on the revenues & profitability of the hotels. Each of our 29 hotels & resorts is managed by a third party. Most are operated under a brand owned by one of the leading global lodging companies: Marriott International, Inc.™, Starwood Hotels & Resorts Worldwide, Inc.™, or Hilton Worldwide™. 

We regularly analyze all of the properties in our portfolio, as well as market conditions, to ensure that we are allocating capital to the highest return opportunities. Our ongoing capital allocation activities include renovation projects, marketing non-core assets for sale & acquisitions. Additionally, our conservative capital structure helps us achieve the optimal balance between value, risk and cost of capital. We seek to further enhance value through efficient corporate overhead, best-in-class corporate governance practices, and openness and transparency in our communications with investors.